Personalis, Inc. (PSNL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$16.40-1.20%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Broken: Primary pillar broken — Achieve full-year 2026 revenue of $78M to $80M: FY26 rev $5.0M vs ~$79M target.
Personalis aims to grow revenue to about $79 million in 2026. The company targets gross margins near 17.5% next year. Recent earnings beats show improving execution. Leadership changes support stable management.
Revenue fell from $17.3M in Q4 2025 to $15.5M in Q1 2026. The company remains unprofitable with negative free cash flow. Growth and margin targets are challenging given current trends.
The market expects about 44% revenue growth, but consensus EPS remains negative. Our fair value at $6.23 reflects this stretched growth view. We see risk in meeting revenue and margin targets.
Breaks if: Clinical volume growth stalls or declines over next 4 quarters
Breaks if: Gross margin falls below 15% in FY26
Breaks if: Annual revenue falls below $75M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a medium confidence level. The company is currently loss-making but is focused on accelerating clinical volume adoption and maintaining revenue guidance.
The market seems to have priced in a justified valuation, with a low expectations gap. However, PSNL trades at a premium compared to its peers, indicating that investors may expect some recovery in performance.
Management is on track with its priorities, particularly in growing clinical test volume and maintaining revenue guidance. However, the company has a history of earnings misses, which adds some near-term risk.
The thesis hinges on whether PSNL can avoid cutting guidance and if broader sector momentum from leading companies can positively influence its performance. Additionally, the impact of economic conditions on healthcare spending will be crucial.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, PSNL's performance will depend on management's execution and external market conditions. Not investment advice.